biomerica.png
Biomerica Receives Notice of Allowance from Canadian Patent Office for Patent Covering Irritable Bowel Syndrome (IBS) Food Sensitivity Testing & Treatment
November 04, 2021 06:39 ET | Biomerica, Inc.
Studies show that 13-20% of Canadians suffer from IBS at any given time1. The lifetime risk for a Canadian to develop IBS is 30%1. IRVINE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc....
biomerica.png
Biomerica expects Completion of Patient Enrollment for its InFoods® Diagnostic-Guided Therapy Irritable Bowel Syndrome Clinical Trial this week
August 30, 2021 08:19 ET | Biomerica, Inc.
Final patients to compete this double blinded trial by end of October. Top-Line trial results expected by year end.The InFoods® IBS Diagnostic-Guided Therapy is the first therapy of its kind for...
biomerica.png
Biomerica Announces Notice of Allowance for Patent on Product used to Diagnose and Treat Depression
August 11, 2021 08:19 ET | Biomerica, Inc.
Hundreds of millions of people worldwide suffer from depression IRVINE, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) announced today that the Japanese Patent Office has...
Logo-InveniAI.png
InveniAI Announces Successful Completion of Milestone in its Collaboration with PRISM BioLab Focused on Designing Novel Inflammasome-Targeted Therapeutic Candidates
July 20, 2021 08:10 ET | InveniAI LLC
- Successful generation of INVA8003, a peptidomimetic inhibitor of PYCARD (often referred to as ASC, apoptosis-associated speck-like protein containing CARD) triggers milestone payment to PRISM BioLab...
biomerica.png
Biomerica Receives Notice of Allowance from Mexican Patent Office for Irritable Bowel Syndrome Food Sensitivity Testing & Treatment
June 15, 2021 08:19 ET | Biomerica, Inc.
IBS is one of the most important gastrointestinal disorders in Mexico, with a prevalence of around 16% [1] (approximately 20 million patients)Broadens InFoods® global patent coverage with recently...
22157.jpg
Global Irritable Bowel Syndrome (IBS) Diagnostics Market Forecast to 2028 - COVID-19 Impact and Analysis
June 09, 2021 06:28 ET | Research and Markets
Dublin, June 09, 2021 (GLOBE NEWSWIRE) -- The "Irritable Bowel Syndrome (IBS) Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Diagnosis (Laboratory Tests, Imaging...
biomerica.png
Biomerica Reports 208% Increase In Q3 Fiscal 2021 Sales, Over Q3 Fiscal 2020
April 15, 2021 10:31 ET | Biomerica, Inc.
Sales increase driven by first sales of COVID-19 Antigen Rapid Test in Europe after January 2021 CE Mark approval Awarded two new patents for InFoods® diagnostic guided therapy technology, including...
22157.jpg
$423.3 Million Worldwide Irritable Bowel Syndrome with Diarrhea Industry to 2028 - Increasing Demand for Spicy Food Will Boost the Drug Market Growth in North America
February 22, 2021 07:23 ET | Research and Markets
Dublin, Feb. 22, 2021 (GLOBE NEWSWIRE) -- The "Irritable Bowel Syndrome with Diarrhea Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive...
biomerica.png
Biomerica Reports Fiscal Year End May 31, 2020 Financial Results
September 01, 2020 08:19 ET | Biomerica, Inc.
Fiscal fourth quarter revenues increase 133.7% over the prior yearFiscal 2020 revenues increase 28.7% over fiscal 2019 New InFoods® patent granted for Singapore IRVINE, Calif., Sept. 01, 2020 ...
biomerica.png
The University of Texas Health Science Center at Houston joins Biomerica’s InFoods® Irritable Bowel Syndrome ("IBS") Diagnostic-Guided Therapy (“DGT”) clinical trial
June 29, 2020 21:39 ET | Biomerica, Inc.
InFoods® Diagnostic-Guided Therapy is designed to identify patient-specific foods that, when removed from the diet, may alleviate an individual's IBS symptoms Approximately 45 million Americans...